Abstract:Background: The economic evaluation of colorectal cancer screening is challenging because of the need to model the underlying unobservable natural history of the disease. Objectives: To describe the available Markov models and to critically analyze their main structural assumptions. Methods: A systematic search was performed in eight relevant databases (MEDLINE, Embase, Econlit, National Health Service Economic Evaluation Database, Health Economic Evaluations Database, Health Technology Assessment database, Cost-Effective Analysis Registry, and European Network of Health Economics Evaluation Databases), identifying 34 models that met the inclusion criteria. A comparative analysis of model structure and parameterization was conducted using two checklists and guidelines for cost-effectiveness screening models. Results: Two modeling techniques were identified. One strategy used a Markov model to reproduce the natural history of the disease and an overlaying model that reproduced the screening process, whereas the other used a single model to represent a screening program. Most of the studies included only adenoma-carcinoma sequences, a few included de novo cancer, and none included the serrated pathway. Parameterization of adenoma dwell time, sojourn time, and surveillance differed between studies, and there was a lack of validation and statistical calibration against local epidemiological data. Most of the studies analyzed failed to perform an adequate literature review and synthesis of diagnostic accuracy properties of the screening tests modeled. Conclusions: Several strategies to model colorectal cancer screening have been developed, but many challenges remain to adequately represent the natural history of the disease and the screening process. Structural uncertainty analysis could be a useful strategy for understanding the impact of the assumptions of different models on cost-effectiveness results.

Instance analysis of Markov model for pharmacoeconomics evaluation

Probabilistic Sensitivity Analysis of Pharmacoeconomics Research Based on Markov Model

A Review of the Method of Performing Pharmacoeconomics Evaluation Using Markov Model and Analysis of Overseas Cases

Markov Model and Meta-Heuristics Combined Method for Cost-Effectiveness Analysis

Application of Path Analysis in Pharmacoeconomics

Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model

An Introduction to Markov Modelling for Economic Evaluation

A Medical Decision Making Study based on Markov Chain Model

[Applications of Markov Model for Cost-Effectiveness Analysis of Screening in Epidemiology].

Critical Analysis of Markov Models Used for the Economic Evaluation of Colorectal Cancer Screening: A Systematic Review

Decision-analytical modelling in health-care economic evaluations

Application of Bayesian Statistics and Markov Model in Medical Decision

System analysis and evaluation of pharmacoeconomic literatures of cancer published in China

Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum

Application of multistate modeling to clinical data analysis

A tutorial on pharmacometric Markov models

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

Application of Markov Process to the Cost-utility Analysis of Medical Intervention Measures

Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit

Modeling therapy sequence for advanced cancer: A microsimulation approach leveraging Electronic Health Record data

Markov models for clinical decision‐making in radiation oncology: A systematic review